<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01121835</url>
  </required_header>
  <id_info>
    <org_study_id>LANTU_C_04589</org_study_id>
    <secondary_id>2009-018172-33</secondary_id>
    <secondary_id>U1111-1116-9859</secondary_id>
    <nct_id>NCT01121835</nct_id>
  </id_info>
  <brief_title>Insulins Glargine and gluLisine strAtegy Versus Premixed Insulin strAteGy: a cOmparative Study</brief_title>
  <acronym>GALAPAGOS</acronym>
  <official_title>A 24-week, Open, Multicenter, Comparative Study of 2 Strategies (Including Insulin Glargine Versus Premixed Insulin) for the Therapeutic Management of Patients With Type 2 Diabetes Failing Oral Agents</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      Primary Objective:

      To demonstrate the superiority of a strategy with insulin glargine in comparison with a
      strategy including the premixed insulin in term of percentage of patients reaching HbA1c
      (glycosylated hemoglobin) below 7% at the end of treatment and who do not experience
      documented symptomatic hypoglycemia (confirmed by a Plasma Glucose (PG) below 56 mg/dL (3.1
      mmol/L)) over a 24-week treatment period, in Type 2 diabetes patients failing lifestyle
      management and oral agents.

      Secondary Objectives:

      To assess the effect of insulin glargine in comparison with premixed insulin on :

        -  Evolution of HbA1c level during the treatment period Percentage of patients who reach
           the target of HbA1c &lt; 7 % and who do not experience documented symptomatic hypoglycemia
           confirmed by a Plasma Glucose (PG) below 70 mg/dL (3.9 mmol/L)

        -  Percentage of patients who reach the target of HbA1c &lt; 6.5% and who do not experience
           documented symptomatic hypoglycemia confirmed by a PG below 56 mg/dL (3.1 mmol/L)
           &gt;Percentage of patients who reach the target of HbA1c &lt; 6.5% and who do not experience
           documented symptomatic hypoglycemia confirmed by a PG below 70 mg/dL (3.9 mmol/L)
           &gt;Evolution of Fasting Plasma Glucose Evolution of 7-point plasma glucose profiles

        -  Evolution of weight

        -  Hypoglycemia occurrence

        -  Dose of insulins

        -  Evolution of liver function

        -  Overall safety
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients with Glycosylated Haemoglobin (HbA1c) &lt;7% with no documented symptomatic hypoglycemia (confirmed by a Plasma Glucose (PG) ≤ 56 mg/dL [3.1 mmol/L]</measure>
    <time_frame>From baseline (visit 2, week 0) to visit 14 (week 24)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>7-point plasma glucose (PG) profile recorded on 3 consecutive days</measure>
    <time_frame>From baseline (visit 2, week 0) to visit 14 (week 24)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self-monitored PG (Plasma Glucose) values over 3 consecutive days</measure>
    <time_frame>before visit 4 (week 2)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self-monitored PG (Plasma Glucose) values over 3 consecutive days</measure>
    <time_frame>before visit 8 (week 6)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self-monitored PG (Plasma Glucose) values over 3 consecutive days</measure>
    <time_frame>before visit 12 (week 16)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight and supine blood pressure</measure>
    <time_frame>From baseline (visit 2, week 0) to visit 14 (week 24)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin doses of the day before each visit</measure>
    <time_frame>from visit 3 (week 1) to visit 14 (week 24)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemistry and lipid profile</measure>
    <time_frame>From baseline (visit 2, week 0) to visit 14 (week 24)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">934</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Insulin glargine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administered once a day in the evening, at the same time every day. The starting daily dose is 0.2 U/Kg of body weight or 12 U, at the investigator's decision.
Insulin glulisine is administered for patients of the insulin glargine group requiring insulin glulisine at week 12 (visit 11).
Insulin glulisine is administered prior (10-15 min) to the main meal of the day, which is the meal with highest Post-Prandial Plasma Glucose (PPPG) on the 3 profiles performed before week 12.
Starting dose is of 4 units per day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Premixed insulin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>administered once a day (in the evening at dinner) or twice a day (in the morning before breakfast and in the evening at dinner). Starting daily dose will be 6 U at breakfast and 6 U at dinner, if administered twice a day or 12 U at dinner if administered once a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INSULIN GLARGINE</intervention_name>
    <description>Pharmaceutical form: solution for injection Route of administration: sub-cutaneous injection Dose regimen: 100 Units/mL solution for injection in a pre-filled SoloStar pen (3 ml)</description>
    <arm_group_label>Insulin glargine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INSULIN GLULISINE</intervention_name>
    <description>Pharmaceutical form: solution for injection Route of administration: sub-cutaneous Dose regimen: 100 Units/mL solution for injection in a pre-filled SoloStar pen (3 mL)</description>
    <arm_group_label>Insulin glargine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PREMIXED INSULIN</intervention_name>
    <description>Pharmaceutical form: solution for injection Route of administration: sub-cutaneous Dose regimen: - 30% soluble insulin aspart and 70 % protamine-crystallised insulin aspart in pre-filled Flexpen for all the countries except Mexico
25 % insulin lispro solution and 75% insulin lispro protamine in cartridges for Humapen Luxura for Mexico only</description>
    <arm_group_label>Premixed insulin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Type 2 diabetes diagnosed for more than 1 year

          -  Insulin naïve

          -  Treated with lifestyle interventions and oral antidiabetic drugs, at least metformin
             at the maximum tolerated dose (with a minimum dose of 1g/day), for at least 3 months

          -  HbA1c ≥ 7.0 % and ≤ 10.5%

          -  Body mass index (BMI) ≤ 40 kg/m2

          -  Ability and willingness to perform plasma glucose (PG) monitoring using the
             sponsor-provided glucose meter and to complete the patient diary

          -  Willingness and ability to comply with the study protocol

          -  Signed informed consent obtained prior any study procedure

        Exclusion criteria:

          -  Treatment with glucagon-like peptide-1 (GLP-1) agonists in the 3 months prior to study
             entry

          -  Previous treatment with insulin (except for treatment of gestational diabetes or brief
             treatment with insulin for less than 1 week)

          -  Diabetes other than type 2 diabetes (e.g. type 1 diabetes, diabetes secondary to
             pancreatic disorders, drug or chemical agent intake)

          -  Pregnant or lactating women (women of childbearing potential must have a negative
             pregnancy test at study entry and a medically approved contraception method)

          -  Hospitalized patient (except for routine diabetes check-up)

          -  Active proliferative retinopathy, as defined by a photocoagulation or vitrectomy
             occurrence in the 6 months prior to study entry, or any other unstable (rapidly
             progressing) retinopathy that may require photocoagulation or surgical treatment
             during the study, documented by retina examination, in the 2 years prior to study
             entry

          -  History of sensitivity to the study drugs or to drugs with a similar chemical
             structure

          -  Impaired renal function: creatinine clearance &lt; 60ml/min

          -  Impaired liver function (ALT, AST &gt; 3 x upper limit of normal range)

          -  Severe gastro-intestinal disease

          -  Treatment with corticosteroids with potential systemic action within the 3 months
             prior to study entry

          -  Likelihood of requiring treatments during the study which are not permitted

          -  Treatment with an investigational product in the 30 days prior to study entry

          -  Alcohol or drug abuse within the last 5 years

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational Site Number 040-004</name>
      <address>
        <city>Sankt Stefan</city>
        <zip>A-8511</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 040-002</name>
      <address>
        <city>Vienna</city>
        <zip>A-1030</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 040-001</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 040-003</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 076002</name>
      <address>
        <city>Belém</city>
        <zip>66073-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 076005</name>
      <address>
        <city>Curitiba</city>
        <zip>80060-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 076004</name>
      <address>
        <city>Fortaleza</city>
        <zip>60430-370</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 076001</name>
      <address>
        <city>Porto Alegre</city>
        <zip>90035-001</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 076003</name>
      <address>
        <city>São Paulo</city>
        <zip>04024-002</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 156004</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 156005</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 156006</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 156011</name>
      <address>
        <city>Chongqing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 156009</name>
      <address>
        <city>Dalian</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 156008</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 156012</name>
      <address>
        <city>Haikou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 156007</name>
      <address>
        <city>Nanjing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 156001</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 156002</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 156003</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 156010</name>
      <address>
        <city>Shenyang</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 170001</name>
      <address>
        <city>Bogota</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 170002</name>
      <address>
        <city>Bogota</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 170003</name>
      <address>
        <city>Bucaramanga</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 170005</name>
      <address>
        <city>Manizales</city>
        <zip>170</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 170004</name>
      <address>
        <city>Pereira</city>
        <zip>170</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 208-001</name>
      <address>
        <city>Hvidovre</city>
        <zip>2650</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 208-003</name>
      <address>
        <city>København NV.</city>
        <zip>2400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 208-002</name>
      <address>
        <city>København S.</city>
        <zip>2300</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 300006</name>
      <address>
        <city>Alexandroupolis</city>
        <zip>68100</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 300001</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 300002</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 300003</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 300004</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 300005</name>
      <address>
        <city>Iraklion</city>
        <zip>71001</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 300011</name>
      <address>
        <city>Maroussi, Athens</city>
        <zip>15123</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 300008</name>
      <address>
        <city>Thessaloniki</city>
        <zip>546 36</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 300010</name>
      <address>
        <city>Thessaloniki</city>
        <zip>56429</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 300007</name>
      <address>
        <city>Thessaloniki</city>
        <zip>57010</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 356008</name>
      <address>
        <city>Bangalore</city>
        <zip>560043</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 356003</name>
      <address>
        <city>Bangalore</city>
        <zip>560052</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 356007</name>
      <address>
        <city>Bangalore</city>
        <zip>560092</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 356006</name>
      <address>
        <city>Bhubaneshwar</city>
        <zip>751019</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 356001</name>
      <address>
        <city>Hyderabad</city>
        <zip>500034</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 356005</name>
      <address>
        <city>Hyderabad</city>
        <zip>500034</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 356004</name>
      <address>
        <city>Trivandrum</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 380-010</name>
      <address>
        <city>Catania</city>
        <zip>95122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 380-008</name>
      <address>
        <city>Catania</city>
        <zip>95124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 380-006</name>
      <address>
        <city>Colleferro</city>
        <zip>00034</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 380-007</name>
      <address>
        <city>Foggia</city>
        <zip>71100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 380-005</name>
      <address>
        <city>Forlì</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 380-001</name>
      <address>
        <city>Genova</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 380-011</name>
      <address>
        <city>Merano</city>
        <zip>39100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 380-009</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 380-012</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 380-004</name>
      <address>
        <city>Parma</city>
        <zip>43100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 410004</name>
      <address>
        <city>Ansan-si, Kyouggi-do</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 410003</name>
      <address>
        <city>Koyang-si</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 410001</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 410002</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 001</name>
      <address>
        <city>Kuwait</city>
        <country>Kuwait</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 484004</name>
      <address>
        <city>Aguascalientes</city>
        <zip>20020</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 484001</name>
      <address>
        <city>Aguascalientes</city>
        <zip>20230</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 484003</name>
      <address>
        <city>Guadalajara</city>
        <zip>44650</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 484002</name>
      <address>
        <city>Guadalajara</city>
        <zip>44680</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 484005</name>
      <address>
        <city>Puebla</city>
        <zip>72000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 642001</name>
      <address>
        <city>Iasi</city>
        <zip>700111</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 642002</name>
      <address>
        <city>Iasi</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 642003</name>
      <address>
        <city>Oradea</city>
        <zip>410169</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 724001</name>
      <address>
        <city>Avila</city>
        <zip>05071</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 724002</name>
      <address>
        <city>Barcelona</city>
        <zip>08022</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 724008</name>
      <address>
        <city>Galdakao</city>
        <zip>48960</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 724007</name>
      <address>
        <city>Lugo</city>
        <zip>27004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 724004</name>
      <address>
        <city>Madrid</city>
        <zip>28805</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 724009</name>
      <address>
        <city>Pamplona</city>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 724005</name>
      <address>
        <city>Santa Coloma de Gramanet</city>
        <zip>8923</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 724003</name>
      <address>
        <city>Sevilla</city>
        <zip>41010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 724006</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 158004</name>
      <address>
        <city>Changhua County</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 158003</name>
      <address>
        <city>Hsintien</city>
        <zip>23137</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 158007</name>
      <address>
        <city>Kaohsiung Hsien,</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 158006</name>
      <address>
        <city>New Taipei city</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 158009</name>
      <address>
        <city>Taichung City</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 158001</name>
      <address>
        <city>Taichung</city>
        <zip>407</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 158005</name>
      <address>
        <city>Tainan</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 158002</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 792-013</name>
      <address>
        <city>Ankara</city>
        <zip>06100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 792-009</name>
      <address>
        <city>Canakkale</city>
        <zip>17110</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 792-006</name>
      <address>
        <city>Diyarbakir</city>
        <zip>21830</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 792-004</name>
      <address>
        <city>Istanbul</city>
        <zip>34098</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 792-001</name>
      <address>
        <city>Izmir</city>
        <zip>35340</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 792-016</name>
      <address>
        <city>Konya</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 792-007</name>
      <address>
        <city>Sivas</city>
        <zip>58140</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 792-005</name>
      <address>
        <city>Trabzon</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 792-002</name>
      <address>
        <city>Van</city>
        <zip>65080</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 784-001</name>
      <address>
        <city>Dubai</city>
        <country>United Arab Emirates</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Brazil</country>
    <country>China</country>
    <country>Colombia</country>
    <country>Denmark</country>
    <country>Greece</country>
    <country>India</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Kuwait</country>
    <country>Mexico</country>
    <country>Romania</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>Turkey</country>
    <country>United Arab Emirates</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 6, 2010</study_first_submitted>
  <study_first_submitted_qc>May 11, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2010</study_first_posted>
  <last_update_submitted>April 2, 2013</last_update_submitted>
  <last_update_submitted_qc>April 2, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 4, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin glulisine</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Glargine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

